Please use this identifier to cite or link to this item:
|Title:||Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs||Authors:||Giuliani, Jacopo
|Keywords:||Anti-angiogenic agents;RCTs;Second-line therapy;mCRC||Keywords Plus:||OXALIPLATIN;BEVACIZUMAB;FLUOROURACIL;COMBINATION;AFLIBERCEPT;PROGRESSION;LEUCOVORIN;SURVIVAL;PHASE-3;TRIAL||Mesh headings:||Angiogenesis Inhibitors;Colorectal Neoplasms||Secondary Mesh headings:||Antineoplastic Combined Chemotherapy Protocols;Clinical Trials, Phase III as Topic;Disease-Free Survival;Drug Costs;Humans;Neoplasm Metastasis;Randomized Controlled Trials as Topic||Issue Date:||Oct-2018||Publisher:||SPRINGER||Journal:||International journal of colorectal disease||Abstract:||
In western Countries, colorectal cancer (CRC) is the second most common cause of death from cancer. In particular, the introduction of active new anti-angiogenic agents for the second-line treatment of metastatic CRC (mCRC) is associated with a relevant increase of costs, and it is therefore important to make a balance between the costs of treatment and the added value represented by the improvement of the clinical parameters of interest such as progression-free survival (PFS).
|Appears in Collections:||Articles|
Show full item record
checked on Jul 15, 2021
checked on Aug 31, 2020
WEB OF SCIENCETM
checked on Nov 24, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.